Roth Positive on Can-Fite Bio Pharma (CANF) Following Completion of CF101 Phase 2/3
Tweet Send to a Friend
Roth Capital affirms Can-Fite Bio Pharma (AMEX: CANF) at Buy with a price target of $20 after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
